C12Y 402/02001
Hyaluronate lyase
Official title: Hyaluronate lyase (4.2.2.1)
C12Y402/02001 (Hyaluronate lyase) appears on 19 US grants and 40 published applications in this corpus.
Search patents in C12Y- Granted patents
- 19
- Published applications
- 40
- Assignees
- 16
- Inventors
- 54
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 1 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 2 |
| 2015 | 0 | 3 |
| 2016 | 1 | 1 |
| 2017 | 2 | 4 |
| 2018 | 1 | 1 |
| 2019 | 1 | 6 |
| 2020 | 6 | 1 |
| 2021 | 1 | 3 |
| 2022 | 1 | 2 |
| 2023 | 0 | 2 |
| 2024 | 0 | 4 |
| 2025 | 0 | 2 |
| 2026 | 2 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Modified bacterial hyaluronidase polypeptide, production process, pharmaceutical compositions and their uses23 Jun 2026US 12,662,664 B2Pharmact Holding AG
- Hyaluronidase variants with improved stability and pharmaceutical composition comprising the same5 May 2026US 12,618,055 B2Alteogen, Inc.
- Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo15 Feb 2022US 11,246,915 B2Applied Molecular Transport Inc.
- Treatment of retinal degeneration using gene therapy9 Feb 2021US 10,912,845 B2The University of Manchester
- Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo13 Oct 2020US 10,799,565 B2Applied Molecular Transport Inc.
- Novel hyaluronidase variants with improved stability and pharmaceutical composition comprising the same9 Jul 2026US 2026/0193632 A1Alteogen, Inc.
- Novel hyaluronidase variants with improved stability and pharmaceutical composition comprising the same9 Jul 2026US 2026/0193633 A1Alteogen, Inc.
- Vaccines targeting c. acnes hyaluronidase for prophylaxis and treatment of acne vulgaris29 Jan 2026US 2026/0027194 A1Cedars-Sinai Medical Center
- Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo14 Aug 2025US 2025/0255938 A1Thornhill Therapeutics, Inc.
- Compositions and methods for enhancing immune cell function using modified cells with glycocalyx editing enzymes15 May 2025US 2025/0152627 A1Cornell University
Most cited
By later US patents
- Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo14US 10,130,688 B2Applied Molecular Transport Inc. · 2018
- Hyaluronate lyase used for promoting penetration in topical agents12US 6,719,986 B1esparma GmbH · 2004
- Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo11US 10,624,955 B2Applied Molecular Transport Inc. · 2020
- Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo11US 10,624,956 B2Applied Molecular Transport Inc. · 2020
- Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo11US 10,624,957 B2Applies Molecular Transport Inc. · 2020